Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open‐label, single‐arm phase <scp>II</scp> study

Srimuninnimit, Vichien; Sriuranpong, Virote; Suwanvecho, Suthida

doi:10.1111/ajco.12191

Cited by 14 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, Liu et al reported that GEMOX combined with sorafenib as first-line therapy followed by sorafenib as maintenance therapy was effective with manageable toxicity for treatment of advanced HCC [150]. Furthermore, the combination of sorafenib and gemcitabine showed modest clinical efficacy with good toleration in advanced HCC [152]. In addition, compared with doxorubicin monotherapy, sorafenib plus doxorubicin resulted in greater median time to progression, overall survival, and progressionfree survival [153].…”

Section: Combination Of Cytotoxic Chemotherapeutic Agentsmentioning

confidence: 99%

Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

et al. 2015

View full text Add to dashboard Cite

Section: Combination Of Cytotoxic Chemotherapeutic Agentsmentioning

confidence: 99%

Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

et al. 2015

View full text Add to dashboard Cite

“…Our previous results [13] revealed that the combination of Sorafenib and chemotherapy may not improve the clinical outcome. A randomized phase II trial comparing Sorafenib alone with Sorafenib plus GEMOX demonstrated that the main objective (4-month PFS rate >50%) was achieved but was comparable in both arms (54% and 64% respectively), and median PFS and OS were not significantly different in the two arms.…”

Section: Discussionmentioning

confidence: 94%

Survival prediction with score model based on clinical characteristics in advanced HCC patients receiving oxaliplatin-containing regimens

Liu

Dong

Zhao

et al. 2019

neo

View full text Add to dashboard Cite

A score model based on clinical characteristics in advanced hepatocellular carcinoma (HCC) patients treated with systemic chemotherapy of oxaliplatin-containing regimens was established to evaluate progression-free survival (PFS) and overall survival (OS). Thirty HCC patients eligible for radical resection were involved in the retrospective study, and these were divided into the good response group (complete response (CR)/partial response (PR) and the poor response group (stable disease (SD)/progression disease (PD). The median PFS and OS were compared in the two groups. PFS and OS combined with clinical characteristics were evaluated by univariate and multivariate analyses. The score model was defined with 1 score for each characteristic, and score model cutoff values were determined by the receiver operating characteristic curve (ROC) which describes treatment response. The median PFS was 10 and 2 months (p<0.001), and the median OS was 13 and 4 months (p=0.011) for the CR/PR and SD/PD groups, respectively. The score of 1 was the optimal cutoff value, with sensitivity ranging from 52.6 to 63.2% and specificity from 81.8 to 100% (AUC= 0.773, p=0.014). The median PFS for good and poor response groups was 9 months and 1month (p<0.001) and the median OS was 22 and 3months at p<0.001, respectively. Patients with scores above 1 had poor response, with median 3 months OS and 1 month PFS, and patients with scores of 0 and 1 established good response, with median 22 months OS and 9 months PFS, respectively.

show abstract

“…Sorafenib has been combined with anti-angiogenic agents, MEK/ERK pathway inhibitors, mTOR pathway inhibitors, histone deacetylase inhibitors, EGF/EGFR pathway inhibitors, and HGF/c-Met pathway inhibitors. 31 Other agents such as interferon, 32 selumetinib, 33 capecitabine, 34 tegafur-uracil, 35 gemcitabine and oxaliplatin (GEMOX), 36 , 37 and gemcitabine alone 38 have also been evaluated but to date no treatments involving combinations containing sorafenib have succeeded in phase III trials.…”

Section: Approved First-line Agents For Hccmentioning

confidence: 99%

Targeted therapy for hepatocellular carcinoma

Huang

Yang

Chung

et al. 2020

Sig Transduct Target Ther

475

298

View full text Add to dashboard Cite

The last 3 years have seen the emergence of promising targeted therapies for the treatment of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a decade and newer modalities were ineffective and did not confer any increased therapeutic benefit until the introduction of lenvatinib which was approved based on its non-inferiority to sorafenib. The subsequent success of regorafenib in HCC patients who progress on sorafenib treatment heralded a new era of second-line treatment and was quickly followed by ramucirumab, cabozantinib, and the most influential, immune checkpoint inhibitors (ICIs). Over the same period combination therapies, including anti-angiogenesis agents with ICIs, dual ICIs and targeted agents in conjunction with surgery or other loco-regional therapies, have been extensively investigated and have shown promise and provided the basis for exciting clinical trials. Work continues to develop additional novel therapeutic agents which could potentially augment the presently available options and understand the underlying mechanisms responsible for drug resistance, with the goal of improving the survival of patients with HCC.

show abstract

Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open‐label, single‐arm phase II study

Cited by 14 publications

References 12 publications

Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

Survival prediction with score model based on clinical characteristics in advanced HCC patients receiving oxaliplatin-containing regimens

Targeted therapy for hepatocellular carcinoma

Contact Info

Product

Resources

About